中文

九典制药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-25
ItemAmountY/Y
Revenue¥0.60B-14.5%
Gross profit¥0.40B
Operating income¥0.06B
Net income¥0.05B-56.9%
Gross margin66.8%Net margin 9.1%
Revenue Q/Q-29.4%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.20B33.2%
R&D¥0.03B5.7%
SG&A¥0.29B49.6%
Tax & other¥0.01B1.1%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

阿石创威唐工业聚灿光电精研科技万隆光电广哈通信永福股份英可瑞凯伦股份*ST泉为华信新材长盛轴承

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies